PULSED DENDRITIC CELLS FOR INDUCTION OF ANTITUMOR IMMUNITY IN MELANOMA PATIENTS

$28,104M01FY2000RRNIH

University Of Virginia Charlottesville, Charlottesville VA

Investigators

Linked publications & trials

Paper 37786359 Paper 36692803 Paper 34035112 Paper 33002231 Paper 32018030 Paper 31505070 Paper 31404238 Paper 29897474 Paper 28340044 Paper 27221649 Paper 26770763 Paper 26258314 Paper 26154337 Paper 25572758 Paper 25359343 Paper 25337923 Paper 25195547 Paper 24973405 Paper 24963646 Paper 24841355 Paper 24793076 Paper 24780043 Paper 24771855 Paper 24756419 Paper 24465565 Paper 24299160 Paper 24285677 Paper 24243632 Paper 23822046 Paper 23657629 Paper 23653149 Paper 23637784 Paper 23531955 Paper 23525391 Paper 23495621 Paper 23384217 Paper 23197414 Paper 22981277 Paper 22966246 Paper 22961574 Paper 22703929 Paper 22579429 Paper 22545071 Paper 22508711 Paper 22474497 Paper 22389002 Paper 22377800 Paper 22232506 Paper 22228772 Paper 22172593 Paper 22167126 Paper 22130163 Paper 22101155 Paper 22082203 Paper 22081303 Paper 22015710 Paper 21988932 Paper 21976537 Paper 21946833 Paper 21911106 Paper 21867844 Paper 21857883 Paper 21816787 Paper 21690475 Paper 21617098 Paper 21570685 Paper 21554109 Paper 21385453 Paper 21377927 Paper 21360253 Paper 21259025 Paper 21194310 Paper 21129332 Paper 21127720 Paper 21114859 Paper 21050619 Paper 21047922 Paper 20929989 Paper 20920442 Paper 20847193 Paper 20727190 Paper 20724335 Paper 20699432 Paper 20624660 Paper 20582734 Paper 20551833 Paper 20516163 Paper 20492363 Paper 20482511 Paper 20434788 Paper 20351592 Paper 20339367 Paper 20216931 Paper 20167444 Paper 20167171 Paper 20144416 Paper 20072145 Paper 20046649 Paper 20005544 Paper 19964353

Abstract

This protocol is a phase I/II trial of melanoma tumor antigen-pulsed autologous dendritic cells administered to patients with metastatic melanoma completing lymphadenectomy. The objectives of this study are to determine whether the proposed regimen (1) can be delivered without significant toxicity, (2) can enhance tumor specific immunity measured in vitro by cytotoxic T cell response and in vivo by delayed type hypersensitivity skin test, and (3) can delay time to progression and positively affect patient survival.

View original record on NIH RePORTER →